FOLH1 and neoplasm: To address the low tumor uptake of the PSMA dimer, we designed DOTA-(2P-PEG4)2, which again adopted a polymeric peptide strategy, aiming to enhance the tumor-targeting ability of the symmetric PSMA dimer.